1. Effect of the leukotriene A4 hydrolase aminopeptidase augmentor 4-methoxydiphenylmethane in a pre-clinical model of pulmonary emphysema
- Author
-
Hye-Sik Kong, Matthew Miessau, Mikell Paige, Kan Wang, Robert J. Snelgrove, Y. Michael Shim, Eliseu O. De Oliveira, and Suhyon Kim
- Subjects
Epoxide hydrolase 2 ,Metabolite ,Clinical Biochemistry ,Pharmaceutical Science ,Biochemistry ,Aminopeptidase ,Article ,Leukotriene-A4 hydrolase ,chemistry.chemical_compound ,Mice ,Drug Discovery ,Animals ,Benzhydryl Compounds ,Epoxide hydrolase ,Molecular Biology ,Lung ,chemistry.chemical_classification ,Epoxide Hydrolases ,Pancreatic Elastase ,Organic Chemistry ,Epoxide hydrolase activity ,Enzyme ,chemistry ,Pulmonary Emphysema ,Molecular Medicine - Abstract
The leukotriene A 4 hydrolase enzyme is a dual functioning enzyme with the following two catalytic activities: an epoxide hydrolase function that transforms the lipid metabolite leukotriene A 4 to leukotriene B 4 and an aminopeptidase function that hydrolyzes short peptides. To date, all drug discovery efforts have focused on the epoxide hydrolase activity of the enzyme, because of extensive biological characterization of the pro-inflammatory properties of its metabolite, leukotriene B 4 . Herein, we have designed a small molecule, 4-methoxydiphenylmethane, as a pharmacological agent that is bioavailable and augments the aminopeptidase activity of the leukotriene A 4 hydrolase enzyme. Pre-clinical evaluation of our drug showed protection against intranasal elastase-induced pulmonary emphysema in murine models.
- Published
- 2011